Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Multiple Sclerosis and Pregnancy: Current Considerations.
Thrombotic microangiopathy associated with use of interferon-beta.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
New Drugs Online report for idebenone
Rituximab product approval information - Licensing action
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Rituximab and multiple sclerosis.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Zebrafish myelination: a transparent model for remyelination?
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Pages